Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC)
Longitudinal Study to Identify Early Biomarkers of Autism Spectrum Disorder (ASD) in Infants With Tuberous Sclerosis Complex (TSC)
Status: Enrolling
Updated:  12/31/1969
The University of Texas, Houston
mi
from
Houston, TX
Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC)
Longitudinal Study to Identify Early Biomarkers of Autism Spectrum Disorder (ASD) in Infants With Tuberous Sclerosis Complex (TSC)
Status: Enrolling
Updated: 12/31/1969
The University of Texas, Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Scalp Application of Red and Near-Infrared Light, From Light-Emitting Diodes (LED) to Improve Thinking and Memory in Veterans With Gulf War Illnesses
Transcranial, Light-Emitting Diode (LED) Therapy to Improve Cognition in GWVI
Status: Enrolling
Updated:  12/31/1969
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
Scalp Application of Red and Near-Infrared Light, From Light-Emitting Diodes (LED) to Improve Thinking and Memory in Veterans With Gulf War Illnesses
Transcranial, Light-Emitting Diode (LED) Therapy to Improve Cognition in GWVI
Status: Enrolling
Updated: 12/31/1969
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
mi
from
Boston, MA
Click here to add this to my saved trials
Scalp Application of Red and Near-Infrared Light, From Light-Emitting Diodes (LED) to Improve Thinking and Memory in Veterans With Gulf War Illnesses
Transcranial, Light-Emitting Diode (LED) Therapy to Improve Cognition in GWVI
Status: Enrolling
Updated:  12/31/1969
San Francisco VA Medical Center, San Francisco, CA
mi
from
San Francisco, CA
Scalp Application of Red and Near-Infrared Light, From Light-Emitting Diodes (LED) to Improve Thinking and Memory in Veterans With Gulf War Illnesses
Transcranial, Light-Emitting Diode (LED) Therapy to Improve Cognition in GWVI
Status: Enrolling
Updated: 12/31/1969
San Francisco VA Medical Center, San Francisco, CA
mi
from
San Francisco, CA
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Alabaster, AL
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Alabaster, AL
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Huntsville, AL
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ocala, FL
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Panama City, FL
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Panama City, FL
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Port Charlotte, FL
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Manhattan, KA
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Manhattan, KA
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Hickory, NC
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Madison, WI
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Casper, WY
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Casper, WY
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mansfield, TX
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mansfield, TX
Click here to add this to my saved trials
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated:  12/31/1969
106
mi
from
East Gosford,
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Status: Enrolling
Updated: 12/31/1969
106
mi
from
East Gosford,
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Hospital
mi
from
Phoenix, AZ
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
San Francisco General Hospital
mi
from
San Francisco, CA
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
San Francisco General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Yale-New Haven Hospital
mi
from
New Haven, CT
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Univ. of Florida College Medicine
mi
from
Jacksonville, FL
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Univ. of Florida College Medicine
mi
from
Jacksonville, FL
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospital
mi
from
Iowa City, IA
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospital
mi
from
Iowa City, IA
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
University of Maryland Medical Center
mi
from
Baltimore, MD
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
mi
from
Boston, MA
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
University of North Carolina Medical Center
mi
from
Chapel Hill, NC
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
University of North Carolina Medical Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Duke University Hospital
mi
from
Durham, NC
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Duke University Hospital
mi
from
Durham, NC
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
The University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
The University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Harborview Medical Center
mi
from
Seattle, WA
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Stanford University Hospital
mi
from
Palo Alto, CA
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Stanford University Hospital
mi
from
Palo Alto, CA
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
University of Massachusetts Memorial Medical Center
mi
from
Worcester, MA
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
University of Massachusetts Memorial Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center
mi
from
Houston, TX
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center
mi
from
Houston, TX
Click here to add this to my saved trials
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated:  12/31/1969
Foothills Medical Center
mi
from
Calgary,
High-Dose Deferoxamine in Intracerebral Hemorrhage
Futility Study of Deferoxamine in Intracerebral Hemorrhage
Status: Enrolling
Updated: 12/31/1969
Foothills Medical Center
mi
from
Calgary,
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10192
mi
from
Cullman, AL
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10192
mi
from
Cullman, AL
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 36
mi
from
Fresno, CA
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 36
mi
from
Fresno, CA
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site
mi
from
Fort Collins, CO
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
mi
from
Fort Collins, CO
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 1298
mi
from
Sarasota, FL
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 1298
mi
from
Sarasota, FL
Click here to add this to my saved trials
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
Teva Investigational Site 10339
mi
from
Fort Wayne, IN
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 10339
mi
from
Fort Wayne, IN
Click here to add this to my saved trials